Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo for $235 per share in cash, or approximately $8.0 billion. Headquartered in Stamford, Connecticut, Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be […]

In in the space of two days in December, Gilead Sciences of Foster City, California announced agreements with two Massachusetts-based biotechs, the first with Scholar Rock of Cambridge and the second with Agenus of Lexington. Gilead will work with Scholar Rock to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation […]

Biogen has announced separate strategic collaborations with C4 Therapeutics (C4T) of Watertown and Skyhawk Therapeutics of Waltham to discover and develop potential new treatments for neurological conditions. C4T is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach […]

Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, has announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed fundraise. With Atlas Venture Opportunity Fund I (AVOF I), the firm will invest in existing Atlas portfolio companies as they progress. “We are delighted and humbled by the […]

Bristol-Myers Squibb and Celgene have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. The Boards of Directors of both companies have approved the combination. The transaction is subject to approval by Bristol-Myers […]